Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Clin |
RCV001590909 | SCV001816151 | uncertain significance | Malignant hyperthermia, susceptibility to, 1 | 2023-04-07 | reviewed by expert panel | curation | This pathogenicity assessment is relevant only for malignant hyperthermia susceptibility (MHS) inherited in an autosomal dominant pattern. Variants in RYR1 can also cause other myopathies inherited in an autosomal dominant pattern or in an autosomal recessive pattern. Some of these disorders may predispose individuals to malignant hyperthermia. RYR1 variants may also contribute to a malignant hyperthermia reaction in combination with other genetic and non-genetic factors and the clinician needs to consider such factors in making management decisions. This sequence variant predicts a substitution of Arginine with Serine at codon 533 of the RYR1 protein, p.(Arg533Ser). This variant is not present in a large population database (gnomAD) at the time this variant was interpreted. No publications were identified that reported this variant in individuals with a personal or family history of MH. The variant is present in ClinVar. No functional studies were identified for this variant. This variant resides in a region of RYR1 considered to be a hotspot for pathogenic variants that contribute to MHS, PM1 (PMID: 21118704). A REVEL score >0.85 (0.86) supports a pathogenic status for this variant, PP3_Moderate. This variant has been classified as a Variant of Unknown Significance. Criteria implemented: PM1, PP3_Moderate. |
Institute of Human Genetics, |
RCV002051701 | SCV000346046 | likely pathogenic | Malignant hyperthermia of anesthesia | no assertion criteria provided | clinical testing |